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Abstract
An Escherichia coli isolate co-producing VIM-4 metallo-b-lactam-
ase and CTX-M-15 extended spectrum b-lactamase was recov-
ered from the urine of a patient with head trauma in Moscow,
Russia. The blaVIM-4 and blaCTX-M-15 genes were carried, respec-
tively, by transmissible plasmids of IncW and IncI1 groups. The
nucleotide sequence of the VIM-4-encoding integron was nearly
identical to that of In416, which represent a large group of
structurally related integrons previously found in Enterobacteria-
ceae all around the Mediterranean basin. This is the first report
of a metallo-b-lactamase-producing E. coli in Russia.
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Resistance of gram-negative bacteria to carbapenems as a
result of their production of acquired metallo-b-lactamases
(MBLs) is an increasing international public health problem
[1]. Among the known types of acquired MBLs, the Verona
integron-encoded MBL (VIM) enzymes are most widely
distributed in different geographical regions and are
represented by more than 30 allotypes (http://www.
lahey.org/studies). These enzymes were first detected in Italy
in 1990s in Pseudomonas aeruginosa but have since emerged
in Enterobacteriaceae [1]. Acquired MBLs are associated with
different mobile elements, and the genes for VIM-type
enzymes are carried as mobile gene cassettes inserted in
class 1 integrons. In Russia, dissemination of MBLs, mostly
VIM-2, was attributed to the clonal spread of Psuedomonas
aeruginosa of sequence type 235 (ST235), and to a lesser
extent, ST234 [2]. In a national multicentre study on antimi-
crobial resistance of nosocomial bacterial pathogens per-
formed in 2006–2008, 122 (11.8%) of 1035 Enterobacteriaceae
isolates were found to be non-susceptible to carbapenems
(imipenem, meropenem or ertapenem) according to Euro-
pean Committee on Antimicrobial Susceptibility Testing (EU-
CAST) criteria; however, none of these isolates were found
to produce MBLs (unpublished data). Here we report for
the first time the isolation of Escherichia coli producing the
VIM-4 MBL.
The multidrug-resistant E. coli 55/1389 isolate was recov-
ered from the urine of a patient with a hospital-acquired uri-
nary tract infection who had been hospitalized for severe
head trauma in a Moscow hospital. No data on the patient’s
history of travel abroad was available.
Susceptibility testing was performed by an agar dilution
method according to CLSI guidelines [3]. The isolate exhibited
high-level resistance to most b-lactam antibiotics tested: ampi-
cillin, piperacillin, piperacillin–tazobactam (4 mg/L fixed inhibi-
tor concentration), cefotaxime, cefoperazone, ceftazidime,
aztreonam, cefoxitin (MICs, ‡256 mg/L) and cefepime (MIC,
128 mg/L). In the presence of clavulanic acid (4 mg/L), the
MICs of cefotaxime, ceftazidime and cefepime were reduced
to 128, 32 and 4 mg/L, respectively. Synergy between oxyimi-
no-cephalosporins and clavulanic acid was also evidenced by
double-disc test, suggesting the presence of an extended spec-
trum b-lactamase (ESBL). Most notably, the isolate demon-
strated decreased susceptibility to carbapenems: ertapenem
(MIC, 2 mg/L), imipenem (MIC, 4 mg/L), meropenem (MIC,
0.5 mg/L) and doripenem (MIC, 0.25 mg/L), although the
MICs of the latter two drugs were still in the susceptibility
range according to both CLSI and EUCAST criteria [3,4]. The
same MIC values were obtained using a broth microdilution
test with standard inoculum (5 · 105 CFU/mL); however, an
increase in inoculum size to 5 · 107 CFU/mL raised the MICs
of all four carbapenems to 64 mg/L, suggesting a strong inocu-
lum effect. Positive results of the modified Hodge test with
meropenem disc and double-disc synergy test between carba-
penems and EDTA indicated the production of an MBL. The
isolate was also resistant to ciprofloxacin (MIC, ‡128 mg/L),
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gentamicin, netilmicin, streptomycin (MICs, ‡256 mg/L), tob-
ramycin, amikacin (MIC, 64 mg/L) and trimethoprim-sulfa-
methoxazole (MIC, 128/2432 mg/L), but was susceptible to
fosfomycin (MIC, 1 mg/L).
The isolate was examined for the genes encoding class A
(TEM, SHV and CTX-M) and class C (MOX, CMY, LAT, BIL,
DHA, ACC, ACT, MIR and FOX) b-lactamases by PCR as
previously described [5–8]. The type of blaCTX-M gene and
its association with the ISEcp1 element were further deter-
mined by direct amplification and sequencing with the prim-
ers listed in Table 1, as described elsewhere [9]. Consistent
with ESBL phenotype, the isolate was found to carry a
blaCTX-M-15 gene downstream of the ISEcp1. No other genes
for ESBLs or AmpC b-lactamases were detected by PCR.
Detection of the MBL gene and characterization of its
genetic environment were performed using a conventional
PCR mapping and sequencing strategy [12] using the primers
listed in Table 1. The MBL-encoding gene of E. coli 55/1389
was identified as blaVIM-4. It was found as the first gene cas-
sette of a class 1 integron and was followed by aacA7, dfrA1,
aadA1 gene cassette with truncated 5¢-end region, and smr
gene cassette. The PCR mapping failed to identify the 3¢
extremity of class 1 integrons (either 3¢-CS or Tn402-like
backbone) downstream of the cassette array but revealed an
insertion of the ISPa21-like element. The 4457-base-pair
sequence of integron obtained from E. coli 55/1389 was
nearly identical to that of In416 (GenBank accession no.
AJ704863), which was previously reported in Enterobacter clo-
acae and Klebsiella pneumoniae from Italy [12]. The only dif-
ference found was a single T/G nucleotide substitution in the
integrase (intI1) gene converting a strong cassette promoter
(PcS) of In416 into a hybrid promoter (PcH1).
VIM-4 is a single amino-acid variant of VIM-1 b-lactamase.
Both enzymes were first described in P. aeruginosa in Italy
(VIM-1) and Greece (VIM-4) [13,14], but were subsequently
identified as the most common integron-encoded MBLs in
Enterobacteriaceae species in several European countries,
especially in Greece, Italy, France and Spain [1]. The blaVIM-
1 and related genes have been described on a variety of in-
tegrons and mobile genetic platforms [15]. Analysis of integ-
ron structures may therefore provide clues about the
origins of the blaVIM-4 gene in E. coli 55/1389. It is important
to note that in addition to In416 mentioned above, several
other integrons found in Enterobacteriaceae from Mediterra-
nean region reveal a similar arrangement of gene cassettes
(Table 2). Some of these integrons closely resemble the
In416 and its variant found in E. coli 55/1389 in that they
contain a characteristic deletion of the 5¢-end part of the
aadA1 gene cassette whereas the others, e.g. In-e541 [16],
carry blaVIM, aacA7, dfrA1 and intact aadA1 cassette fol-
lowed by the typical 3¢-CS sequence. This probably indi-
cates that the In416 have descended from a ‘classical’ In-
e541 integron via initial deletion in the aadA1 gene cassette
and subsequent recombination in its 3¢ vicinity, which
resulted in acquisition of the smr gene and an ISPa21-like
element.
To determine whether the blaCTX-M-15 and blaVIM-4 genes
are located on transmissible plasmids in E. coli 55/1389, con-
jugation experiments were performed in broth cultures using
a rifampicin-resistant E. coli AB1456 strain [26] as recipient.
Transconjugants were selected with rifampicin (100 mg/L)
plus ampicillin (40 mg/L). The plasmid contents of the donor
isolate and transconjugants were analysed by pulsed-field gel
electrophoresis following S1 nuclease treatment as previously
described [27]. Hybridization with blaCTX-M-specific and
blaVIM-specific probes generated by PCR was also performed
[22]. Plasmid incompatibility groups were determined by a
PCR-based typing method [28]. Five plasmid replicons were
detected in E. coli 55/1389: I1, FIA, FIB, W and F; whereas in
transconjugants, only I1 and W were detected, either alone
or in combination. Both b-lactamase genes were transferable:
the blaCTX-M-15 was identified on an IncI1 plasmid of
TABLE 1. Primers used for PCR
mapping and sequencing of b-lac-
tamase genes and their environ-
ments
Primer Sequence 5¢–3¢ Target Reference
CTX-M/Rstop CTATTACAAACCGTCGGTGAC blaCTX-M [10]
ISEcp1 TGTCTGGTATAATAAGAATATCATC tnpA of ISEcp1 [10]
VIM-Fa GTTTGGTCGCATATCGC blaVIM This study
VIM-Ra TCGTCATGAAAGTGCGT blaVIM This study
VIM-OUT-F CTACCCGGAAGCACAGTTCGTC blaVIM This study
VIM-OUT-R ACCGGAATTTCGCTGACTGTCG blaVIM This study
INT/5CS CTTCTAGAAAACCGAGGATGC intI1 [11]
3-CS QAC-EXT AATGCGGATGTTGCGATTAC qacED1 [12]
TniC-rev GTGGGCGATCTCTGCGAAG tniC of Tn5090 This study
ISPa21-rev TGATCGAGCGTCCGGAAGTCTG tnpA of ISPa21 This study
SMR-rev ATGCCCGTCCAAACAGCGTAGG smr This study
dhfr-fw AATGGAGTTATCGGGAATGG dhfr1 This study
dhfr-rev GTCTTGCGTCCAACCAACAGCC dhfr1 This study
aadA1-fw CGATGAGCGAAATGTAGTGC aadA1 This study
aadA1-rev GAAAGGCGAGATCACCAAGG aadA1 This study
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c. 300 kilobases, and the blaVIM-4 was associated with an
IncW plasmid of c. 40 kilobases.
It is interesting to note that despite the fact that the VIM-
4-encoding integron, In416, has been reported to be located
on an IncA/C plasmid in K. pneumoniae [12], its possible pre-
decessor, In-e541, has been found on plasmids of different
incompatibility groups, including IncN in E. coli [29,30] and,
most notably, IncW in Serratia liquefaciens and Klebsiella oxyt-
oca [31]. Hence, our study further supports the role of IncW
plasmids in spreading the blaVIM genes in Enterobacteriaceae.
To our knowledge, this is the first report of MBLs in an
Enterobacteriaceae isolate in Russia. Although there is no epi-
demiological evidence, we can consider import from the
Mediterranean region were VIM-4-encoding or VIM-1-encod-
ing class 1 integrons highly similar to that found in our case
isolate have been identified in various gram-negative bacteria.
The co-production of a VIM-type MBL and a CTX-M-type
ESBL in Enterobacteriaceae, rendering resistance to all b-lac-
tams including aztreonam, which has been noted in several
earlier reports is particularly worrying.
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